The Board of Directors of the Company at its meeting held on 30/06/2025 ,inter alia, considered and approved various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date, timing of the Rights Issue and other terms and conditions with respect to the Rights Issue, subject to the receipt of In-Principle approval from the Stock Exchanges or such other Regulatory Authorities as may be required
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 2.8 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Astec LifeSciences, at its meeting on 30th June 2025, finalised the terms of a Rights Issue to raise up to Rs. 250 Crore. The company will issue 28,01,673 equity shares at Rs. 890 per share (including a premium of Rs. 880), in the ratio of 1 rights share for every 7 shares held by eligible shareholders. The record date is fixed as 4th July 2025. The issue will open on 14th July 2025 and close on 28th July 2025, subject to In-Principle approval from stock exchanges and other regulators. Post-issue, the total share count will rise from 1.96 crore to about 2.24 crore equity shares, assuming full subscription.
If fully subscribed, existing shareholders will see a dilution of roughly 14.3% in their holding. Eligible shareholders must decide by 28th July 2025 whether to subscribe, renounce, or let their entitlements lapse. The Rs. 890 issue price and terms will be key for shareholders to evaluate against the prevailing market price.